Skip to main content
SpringerLink
Log in

Molecular Diagnosis and Targeted Therapy for Gastric Cancer

  • Chapter
  • First Online:
Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy

Part of the book series: Current Human Cell Research and Applications ((CHCRA))

  • 481 Accesses

Abstract

Gastric cancer (GC) is a heterogeneous cancer with widely varied outcome and similar clinical and pathological features in Caucasians and Asians. The treatment results from Asian countries seem to be better than those of Western countries. There is an urgent need to clarify the differences in results between Eastern and Western countries and to determine the best management of patients with GC. Now, the molecular biology of cancer is gradually becoming clear. Molecular-targeted drugs are on the rise, and classifications corresponding to the biomarkers of these drugs are beginning to be used in clinical settings. In addition, huge quantities of genome information are gradually being analyzed in a short time with the appearance of next-generation sequencers that can identify gene variation and copy number abnormalities. Now, because a classification based on the characteristics of the genome level of GC has been reported, we review the latest information on GC.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet-Tieulent J, Jemal A. Global cancer statistics, 2012. CA Cancer J Clin. 2015;65(2):87–108.

    Article  PubMed  Google Scholar 

  2. Ito Y, Ioka A, Tanaka M, Nakayama T, Tsukuma H. Trends in cancer incidence and mortality in Osaka, Japan: evaluation of cancer control activities. Cancer Sci. 2009;100:2390–5.

    Article  CAS  PubMed  Google Scholar 

  3. Nomura A, Stemmermann GN, Chyou PH, Kato I, Perez GI, Blaser MJ. Helicobacter pylori infection and gastric carcinoma among Japanese Americans in Hawaii. N Engl J Med. 1991;325:1132–6.

    Article  CAS  PubMed  Google Scholar 

  4. Parsonnet J, Friedman GD, Vandersteen DP, Chang Y, Vogelman JH, Orentreich N, et al. Helicobacter pylori and the risk of gastric carcinoma. N Engl J Med. 1991;325:1127–31.

    Article  CAS  PubMed  Google Scholar 

  5. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med. 2001;345:784–9.

    Article  CAS  PubMed  Google Scholar 

  6. Kudo M, Asaka M, Kato M, Katagiri M, Kagaya H, Nishikawa K, et al. Role of helicobacter pylori in chronic gastritis: a prospective study. J Clin Gastroenterol. 1995;21(Suppl 1):S174–8.

    Google Scholar 

  7. Asaka M, Kudo M, Kato M, Kimura T, Meguro T, Mitani S, et al. The role of helicobacter pylori infection in the pathogenesis of gastritis. J Gastroenterol. 1994;29(Suppl 7):100–4.

    Google Scholar 

  8. Haruma K, Komoto K, Kawaguchi H, Okamoto S, Yoshihara M, Sumii K, et al. Pernicious anemia and helicobacter pylori infection in Japan: evaluation in a country with a high prevalence of infection. Am J Gastroenterol. 1995;90(7):1107–10.

    Google Scholar 

  9. Kuwahara Y, Kono S, Eguchi H, Hamada H, Shinchi K, Imanishi K. Relationship between serologically diagnosed chronic atrophic gastritis, helicobacter pylori, and environmental factors in Japanese men. Scand J Gastroenterol. 2000;35(5):476–81.

    Article  CAS  PubMed  Google Scholar 

  10. Fukuda S, Tanaka M, Soma Y, Shimoyama T, Mikami T, Crabtree JE, et al. Histological analysis of gastritis and helicobacter pylori infection in patients with early gastric cancer: a case-control study. J Gastroenterol Hepatol. 2000;15(12):1370–6.

    Google Scholar 

  11. Schistosomes, liver flukes and helicobacter pylori. IARC working group on the evaluation of carcinogenic risks to humans. Lyon, 7-14 June 1994. IARC Monogr Eval Carcinog Risks Hum. 1994;61:1–241.

    Google Scholar 

  12. Kuipers EJ, Uyterlinde AM, Pena AS, Roosendaal R, Pals G, Nelis GF, et al. Long-term sequelae of helicobacter pylori gastritis. Lancet. 1995;345:1525–8.

    Google Scholar 

  13. Helicobacter and Cancer Collaborative Group. Gastric cancer and helicobacter pylori: a combined analysis of 12 case-control studies nested within prospective cohorts. Gut. 2001;49:347–53.

    Article  Google Scholar 

  14. Eslick GD, Lim LL, Byles JE, Xia HH, Talley NJ. Association of Helicobacter pylori infection with gastric carcinoma: a meta-analysis. Am J Gastroenterol. 1999;94:2373–9.

    Article  CAS  PubMed  Google Scholar 

  15. Huang JQ, Sridhar S, Chen Y, Hunt RH. Meta-analysis of the relationship between helicobacter pylori seropositivity and gastric cancer. Gastroenterology. 1998;114:1169–79.

    Article  CAS  PubMed  Google Scholar 

  16. Hatakeyama M. Helicobacter pylori CagA and gastric cancer: a paradigm for hit-and-run carcinogenesis. Cell Host Microbe. 2014;15(3):306–16.

    Article  CAS  PubMed  Google Scholar 

  17. Covacci A, Censini S, Bugnoli M, Petracca R, Burroni D, Macchia G, et al. Figura N molecular characterization of the 128-kDa immunodominant antigen of helicobacter pylori associated with cytotoxicity and duodenal ulcer. Proc Natl Acad Sci U S A. 1993;90(12):5791–5.

    Google Scholar 

  18. Hatakeyama M. Oncogenic mechanisms of the helicobacter pylori CagA protein. Nat Rev. Cancer. 2004;4(9):688–94. Review

    Article  CAS  PubMed  Google Scholar 

  19. Blaser MJ, Perez-Perez GI, Kleanthous H, Cover TL, Peek RM, Chyou PH, et al. Infection with helicobacter pylori strains possessing cagA is associated with an increased risk of developing adenocarcinoma of the stomach. Cancer Res. 1995;55:2111–5.

    Google Scholar 

  20. Parsonnet J, Friedmann GD, Orentreich N, Vogelman H. Risk for gastric cancer in people with CagA positive or CagA negative helicobacter pylori infection. Gut. 1997;40:279–301.

    Article  Google Scholar 

  21. Enroth H, Kraaz W, Engstrand L, Nyren O, Rohan T. Helicobacter pylori strain types and risk of gastric cancer: a case-control study. Cancer Epidemiol Biomark Prev. 2000;9:981–4.

    CAS  Google Scholar 

  22. Hatakeyama M. Helicobacter pylori and gastric carcinogenesis. J Gastroenterol. 2009;44(4):239–48.

    Google Scholar 

  23. Hatakeyama M. Anthropological and clinical implications for the structural diversity of the helicobacter pylori CagA oncoprotein. Cancer Sci. 2011;102(1):36–43.

    Article  CAS  PubMed  Google Scholar 

  24. Vilaichone RK, Mahachai V, Tumwasorn S, Wu JY, Graham DY, Yamaoka Y. Molecular epidemiology and outcome of helicobacter pylori infection in Thailand: a cultural cross roads. Helicobacter. 2004;5:453–9.

    Article  Google Scholar 

  25. Truong BX, Mai VT, Tanaka H, et al. Diverse characterization of the cagA gene of helicobacter pylori strains in gastric cancer and peptic ulcer patients from southern Vietnam. J Clin Microbiol. 2009;47:4021–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Schmidt HM, Goh KL, Fock KM, et al. Distinct cagA EPIYA motifs are associated with ethnic diversity in Malaysia and Singapore. Helicobacter. 2009;14:256–63.

    Article  CAS  PubMed  Google Scholar 

  27. Saito Y, Murata-Kamiya N, Hirayama T, Ohba Y, Hatakeyama M. Conversion of helicobacter pylori CagA from senescence inducer to oncogenic driver through polarity-dependent regulation of p21. J Exp Med. 2010;201:2154–74.

    Google Scholar 

  28. Hanahan D, Weinberg RA. The hallmark of cancer. Cell. 2000;100:57–70.

    Article  CAS  PubMed  Google Scholar 

  29. Muto S, Hata M, Taniguchi J, et al. Claudin-2-deficient mice are defective in the leaky and cation-selective paracellular permeability properties of renal proximal tubules. Proc Natl Acad Sci U S A. 2010;107:8011–6.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Tamura A, Hayashi H, Imasato M, et al. Loss of claudin-15, but not claudin-2, causes Na_ deficiency and glucose malabsorption in mouse small intestine. Gastroenterology. 2011;140:913–23.

    Article  CAS  PubMed  Google Scholar 

  31. Madara JL. Regulation of the movement of solutes across tight junctions. Annu Rev. Physiol. 1998;60:143–59.

    Article  CAS  PubMed  Google Scholar 

  32. Umeda K, Ikenouchi J, Katahira-Tayama S, et al. ZO-1 and ZO-2 independently determine where claudins are polymerized in tight junction strand formation. Cell. 2006;126:741–54.

    Article  CAS  PubMed  Google Scholar 

  33. Sanada Y, Oue N, Mitani Y, et al. Down-regulation of the claudin-18 gene, identified through serial analysis of gene expression data analysis, in gastric cancer with an intestinal phenotype. J Pathol. 2006;208:633–42.

    Article  CAS  PubMed  Google Scholar 

  34. Hayashi D, Tamura A, Tanaka H, Yamazaki Y, Watanabe S, Suzuki K, et al. Deficiency of claudin-18 causes paracellular H+ leakage, up-regulation of interleukin-1β, and atrophic gastritis in mice. Gastroenterology. 2012;142(2):292–304.

    Google Scholar 

  35. Lee J, Ou SH. Towards the goal of personalized medicine in gastric cancer-time to move beyond HER2 inhibition. Part II: Targeting gene mutations and gene amplifications and the angiogenesis pathway. Discov Med. 2013:16(86):7–14.

    Google Scholar 

  36. Lee JW, Soung YH, Kim SY, Park WS, Nam SW, Kim SH, et al. ERBB2 kinase domain mutation in a gastric cancer metastasis. APMIS. 2005;113(10):683–7.

    Google Scholar 

  37. Gravalos C, Jimeno A. HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol. 2008;19:1523–9.

    Article  CAS  PubMed  Google Scholar 

  38. Yonemura Y, Ninomiya I, Yamaguchi A, Fushida S, Kimura H, Ohoyama S, et al. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer. Cancer Res. 1991;51:1034–8.

    CAS  PubMed  Google Scholar 

  39. Allgayer H, Babic R, Gruetzner KU, Tarabichi A, Schildberg FW, Heiss MM. C-erbB-2 is of independent prognostic relevance in gastric cancer and is associated with the expression of tumor associated protease systems. J Clin Oncol. 2000;18:2201–9.

    Article  CAS  PubMed  Google Scholar 

  40. Bang Y, Chung H, Xu J, Lordick F, Sawaki A, Lipatov O, et al. Pathological features of advanced gastric cancer (GC): relationship to human epidermal growth factor receptor 2 (HER2) positivity in the global screening programme of the ToGA trial. J Clin Oncol. 2009;27(suppl):abstr#4556.

    Google Scholar 

  41. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Rüschoff J, Kang YK; ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-esophageal junction cancer (ToGA): a phase 3 open-label randomized controlled trial. Lancet 2010;376(9742):687–697.

    Google Scholar 

  42. Galizia G, Lieto E, Orditura M, Castellano P, Mura AL, Imperatore V, et al. Epidermal growth factor receptor (EGFR) expression is associated with a worse prognosis in gastric cancer patients undergoing curative surgery. World J Surg. 2007;31:1458–68.

    Article  PubMed  Google Scholar 

  43. Kim MA, Lee HS, Lee HE, Jeon YK, Yang HK, Kim WH. EGFR in gastric carcinomas: prognostic significance of protein overexpression and high gene copy number. Histopathology. 2008;52:738–46.

    Article  CAS  PubMed  Google Scholar 

  44. Hayashi M, Inokuchi M, Takagi Y, Yamada H, Kojima K, Kumagai J, et al. High expression of HER3 is associated with a decreased survival in gastric cancer. Clin Cancer Res. 2008;14:7843–9.

    Article  CAS  PubMed  Google Scholar 

  45. Terashima M, Kitada K, Ochiai A, Ichikawa W, Kurahashi I, Sakuramoto S, et al. Impact of expression of human epidermal growth factor receptors EGFR and ERBB2 on survival in stage II/III gastric cancer. Clin Cancer Res. 2012;18:5992–6000.

    Article  CAS  PubMed  Google Scholar 

  46. Lee HE, Kim MA, Lee HS, Jung EJ, Yang HK, Lee BL, et al. MET in gastric carcinomas: comparison between protein expression and gene copy number and impact on clinical outcome. Br J Cancer. 2012;107:325–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  47. Ha SY, Lee J, Kang SY, Do IG, Ahn S, Park JO, et al. MET overexpression assessed by new interpretation method predicts gene amplification and poor survival in advanced gastric carcinomas. Mod Pathol. 2013;26:1632–41.

    Article  CAS  PubMed  Google Scholar 

  48. Fuse N, Kuboki Y, Kuwata T, Nishina T, Kadowaki S, Shinozaki E, et al. Prognostic impact of HER2, EGFR, and c-MET status on overall survival of advanced gastric cancer patients. Gastric Cancer. 2016;19(1):183–91.

    Google Scholar 

  49. Lu D, Jimenez X, Zhang H, Bohlen P, Witte L, Zhu Z. Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy. Int J Cancer. 2002;97:393–9.

    Article  CAS  PubMed  Google Scholar 

  50. Van Cutsem E, de Haas S, Kang YK, Ohtsu A, Tebbutt NC, Ming Xu J, et al. Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a biomarker evaluation from the AVAGAST randomized phase III trial. J Clin Oncol. 2012;30:2119–27.

    Article  PubMed  Google Scholar 

  51. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014;383:31–9.

    Article  CAS  PubMed  Google Scholar 

  52. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, Hironaka S, Sugimoto N, Lipatov O, Kim TY, Cunningham D, Rougier P, Komatsu Y, Ajani J, Emig M, Carlesi R, Ferry D, Chandrawansa K, Schwartz JD, Ohtsu A; RAINBOW Study Group. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial. Lancet Oncol 2014;15(11):1224–1235.

    Google Scholar 

  53. Javle M, Smyth EC, Chau I. Ramucirumab: successfully targeting angiogenesis in gastric cancer. Clin Cancer Res. 2014;20(23):5875–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Nakamura K, Sugano H, Takagi K. Carcinoma of the stomach in incipient phase: its histogenesis and histological appearances. Gan. 1968;59:251–8.

    CAS  PubMed  Google Scholar 

  55. Lauren P. The two histological main types of gastric carcinoma. Diffuse and so-called intestinal type carcinoma: an attempt at histological classification. Acta Pathol Microbiol Scand. 1965;64:31–49.

    Article  CAS  PubMed  Google Scholar 

  56. Vauhkonen M, Vauhkonen H, Sipponen P. Pathology and molecular biology of gastric cancer. Best Pract Res Clin Gastroenterol. 2006;20:651–74.

    Article  CAS  PubMed  Google Scholar 

  57. Yasui W, Oue N, Ito R, Kuraoka K, Nakayama H. Search for new biomarkers of gastric cancer through serial analysis of gene expression and its clinical implications. Cancer Sci. 2004;95:385–92.

    Article  CAS  PubMed  Google Scholar 

  58. Yasui W, Sentani K, Sakamoto N, Anami K, Naito Y, Oue N. Molecular pathology of gastric cancer: research and practice. Pathol Res Pract. 2011;207:608–12.

    Article  CAS  PubMed  Google Scholar 

  59. Oue N, Oshimo Y, Nakayama H, et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci. 2003;94:901–5.

    Article  CAS  PubMed  Google Scholar 

  60. Oue N, Sentani K, Sakamoto N, Yasui W. Clinicopathologic and molecular characteristics of gastric cancer showing gastric and intestinal mucin phenotype. Cancer Sci. 2015;106(8):951–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  61. Endoh Y, Tamura G, Watanabe H, Ajioka Y, Motoyama T. The common 18-base pair deletion at codons 418–423 of the E-cadherin gene in differentiated-type adenocarcinomas and intramucosal precancerous lesions of the stomach with the features of gastric foveolar epithelium. J Pathol. 1999;189:201–6.

    Article  CAS  PubMed  Google Scholar 

  62. Shibata N, Watari J, Fujiya M, Tanno S, Saitoh Y, Kohgo Y. Cell kinetics and genetic instabilities in differentiated type early gastric cancers with different mucin phenotype. Hum Pathol. 2003;34:32–40.

    Article  CAS  PubMed  Google Scholar 

  63. Sentani K, Matsuda M, Oue N, et al. Clinicopathological significance of MMP-7, laminin gamma2 and EGFR expression at the invasive front of gastric carcinoma. Gastric Cancer. 2014;17:412–22.

    Article  CAS  PubMed  Google Scholar 

  64. Kakiuchi M, Nishizawa T, Ueda H, et al. Recurrent gain-of-function mutations of RHOA in diffuse-type gastric carcinoma. Nat Genet. 2014;46:583–7.

    Article  CAS  PubMed  Google Scholar 

  65. Forbes SA, Beare D, Gunasekaran P, et al. COSMIC: exploring the world’s knowledge of somatic mutations in human cancer. Nucleic Acids Res. 2015;43:D805–11.

    Article  CAS  PubMed  Google Scholar 

  66. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–9.

    Article  Google Scholar 

  67. Ferlay J, Soerjomataram I, Ervik M, et al. Cancer incidence and mortality worldwide: IARC CancerBase No. 11; 2013.

    Google Scholar 

  68. Greenlee RT, Hill-Harmon MB, Murray T, et al. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15–36.

    Article  CAS  PubMed  Google Scholar 

  69. Lee WJ, Lee WC, Houng SJ, et al. Survival after resection of gastric cancer and prognostic relevance of systematic lymph node dissection: twenty years experience in Taiwan. World J Surg. 1995;19:707–13.

    Article  PubMed  Google Scholar 

  70. Mok YJ, Koo BW, Whang CW, et al. Cancer of the stomach: a review of two hospitals in Korea and Japan. World J Surg. 1993;17:777–82.

    Article  CAS  PubMed  Google Scholar 

  71. Fuchs CS, Mayer RJ. Gastric carcinoma. N Engl J Med. 1995;333:32–41.

    Article  CAS  PubMed  Google Scholar 

  72. Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base Report on poor survival of U.S. gastric carcinoma patients treated with gastrectomy: fifth edition American joint committee on cancer staging, proximal disease, and the “different disease” hypothesis. Cancer. 2000;88:921–32.

    Article  CAS  PubMed  Google Scholar 

  73. Lin SJ, Gagnon-Bartsch JA, Tan IB, Earle S, Ruff L, Pettinger K, et al. Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas. Gut. 2015;64(11):1721–31.

    Google Scholar 

  74. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed death- receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomized dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.

    Article  CAS  PubMed  Google Scholar 

  75. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32:1020–30.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  76. Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. N Engl J Med. 2015;373:123–35.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  77. Motzer RJ, Escudier B, McDermott DF, et al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N Engl J Med. 2015;373:1803–13.

    Article  CAS  PubMed  Google Scholar 

  78. FDA; 2016. Available online: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm?fuseaction=Search.Label_ApprovalHistory

  79. Larkin J, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1.

    Article  PubMed  Google Scholar 

  80. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, et al. Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncol. 2016;17(7):956–65.

    Google Scholar 

  81. Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.

    Google Scholar 

  82. Muro K, Chung HC, Shankaran V, Geva R, Catenacci D, Gupta S, Eder JP, Golan T, Le DT, Burtness B, McRee AJ, Lin CC, Pathiraja K, Lunceford J, Emancipator K, Juco J, Koshiji M, Bang YJ. Pembrolizumab for patients with PD-L1-positive advanced gastric cancer (KEYNOTE-012): a multicentre, open-label, phase 1b trial. Lancet Oncol. 2016;17(6):717–26.

    Google Scholar 

  83. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, Iwasaki Y, Hyung WJ, Takagane A, do Park J, Yoshikawa T, Hahn S, Nakamura K, Park CH, Kurokawa Y, Bang YJ, Park BJ, Sasako M, Tsujinaka T; REGATTA study investigators. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol 2016;17(3):309–318.

    Google Scholar 

  84. Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–38.

    Article  PubMed  Google Scholar 

  85. Yamaguchi K, Yoshida K, Tanaka Y, Matsuhashi N, Toshiyuki T, Takahashi T. Conversion therapy for stage IV gastric cancer-the present and future. Transl Gastroenterol Hepatol. 2016;1:50.

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Disclosures

K. Yoshida has received honoraria for lecture from Chugai Pharmaceutical Co., Ltd.; Taiho Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Eli Lilly and Company; Daiichi Sankyo Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Merck Serono Co., Ltd.; and Novartis Pharma K.K.; Sanofi K.K. and research funding from Ajinomoto Pharmaceutical Co., Ltd.; Takeda Pharmaceutical Co., Ltd.; Chugai Pharmaceutical Co., Ltd.; Daiichi Sankyo Co., Ltd.; Taiho Pharmaceutical Co.; Ono Pharmaceutical Co.; and Yakult Honsha Co., Ltd., outside the submitted work. All remaining authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Surgical Oncology, Gifu University Graduate School of Medicine, 1-1 Yanagido, Gifu City, 501-1194, Japan

    Nobuhisa Matsuhashi, Kazuhiro Yoshida, Kazuya Yamaguchi & Toshiyuki Tanahashi

Authors
  1. Nobuhisa Matsuhashi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Kazuhiro Yoshida
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Kazuya Yamaguchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toshiyuki Tanahashi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kazuhiro Yoshida .

Editor information

Editors and Affiliations

  1. Department of Nanobio Drug Discovery, Kyoto University, Sakyo-ku, Kyoto, Japan

    Yutaka Shimada

  2. Department of Surgery, Jikei University School of Medicine, Minato-ku, Tokyo, Japan

    Katsuhiko Yanaga

Rights and permissions

Reprints and permissions

Copyright information

© 2018 Springer Nature Singapore Pte Ltd.

About this chapter

Cite this chapter

Matsuhashi, N., Yoshida, K., Yamaguchi, K., Tanahashi, T. (2018). Molecular Diagnosis and Targeted Therapy for Gastric Cancer. In: Shimada, Y., Yanaga, K. (eds) Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. Current Human Cell Research and Applications. Springer, Singapore. https://doi.org/10.1007/978-981-10-6469-2_4

Download citation

  • DOI: https://doi.org/10.1007/978-981-10-6469-2_4

  • Published:

  • Publisher Name: Springer, Singapore

  • Print ISBN: 978-981-10-6468-5

  • Online ISBN: 978-981-10-6469-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation